Products
    • Products

    TruSight Oncology 500 clinical research solutions

    Take cancer from uncertainty to insight

    Enable comprehensive genomic profiling from tissue or liquid biopsies for clinical research

    Profile image of a female scientist using a single pipette into a tube, two boxes of TruSight Oncology ctDNA v2 Enrichment library prep boxes on the lab bench with other NovaSeq X consumables; two scientists and a NovaSeq X instrument are blurry in the background.

    Three assays to fuel precision oncology research

    The TruSight Oncology 500 product line offers pan-cancer next-generation sequencing assays to enable in-house comprehensive genomic profiling (CGP). Identify relevant biomarkers from key guidelines and clinical trials with one consolidated assay to get more results with less sample than iterative testing. 

    TruSight Oncology 500 products

    TruSight Oncology 500

    Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI, and HRD) from FFPE tissue.

    TruSight Oncology 500 High-Throughput

    Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI) from FFPE tissue, with added scalability.

    TruSight Oncology 500 ctDNA v2

    Enable CGP with a pan-cancer panel capable of detecting key IO gene signatures (TMB, MSI) plus all main variant classes from ctDNA in blood plasma.

    Key features and benefits

    Comprehensive

    Assess > 500 pan-cancer biomarkers in a single multiplex assay, including broad genomic signatures like TMB, MSI and HRD* to increase the likelihood of identifying a relevant mutation without sequential testing.

    Flexibility

    Use FFPE samples or minimally invasive circulating tumor DNA (ctDNA) from liquid biopsy to complement tissue studies or if sufficient tissue is not readily available.

    Reliability

    Achieve consistent quality across the portfolio with robust hybrid capture chemistry, proven SBS sequencing and sophisticated bioinformatics.

    In-house

    Offer precision oncology in your lab to minimize sample loss, control turnaround times, monitor quality, and retain data for reanalysis as discoveries are made.

    Timely

    Obtain results in < 5 days with integrated library prep, sequencing, and bioinformatics options available locally or in the cloud.

    Scalable

    Reduce hands-on time and minimize errors with automation options. Sequence 8–192 samples per run for TruSight Oncology and TruSight Oncology High-Throughput† and 8–48 samples per run for TruSight Oncology 500 ctDNA.

    Key biomarkers

    Subset of genomic tumor profiling biomarkers for multiple cancer typesa

    Pan-cancer: BRAF NTRK1 NTRK2 NTRK3 RET MSI TMB

    Genes with biomarkers of significanceb Genes with biomarkers of
    potential significancec
      Breast BRCA1 BRCA2 ERBB2 ESR1 PALB2 PIK3CA 180
      Colorectal ERBB2 KRAS NRAS       166
      Bone EGFR ERG ETV1 ETV4 EWSR1 FEV 140
    FLI1 FUS H3F3A HEY1 IGH1 MDM2
    ERBB2 NCOA2 SMARCB1      
      Lung ALK EGFR ERBB2 KRAS MET NUTM1 223
    ROS1          
      Melanoma KIT NRAS ROS1       172
      Ovarian BRCA1 BRCA2 FOXL2       149
      CNSd APC ATRX CDKN2A CDKN2B EGFR H3F3A 140
    HIST1H3B HIST1H3C IDH1 IDH2 MYCN PTCH1
    RELA TERT TP53      
      Prostate AR ATM BARD1 BRCA1 BRCA2 BRIP1 151
    CDK12 CHEK1 CHEK2 FANCL FGFR2 FGFR3
    PALB2 RAD51B RAD51C RAD51D RAD54L  
      Thyroid HRAS KRAS NRAS RET TERT   165
      Uterine & cervical BRCA2 EPC1 ERBB2 ESR1 FOXO1 GREB1 138
    JAZF1 NCOA2 NCOA3 NUTM2A NUTM2B PAX3
    PAX7 PHF1 POLE SMARCA4 SUZ12 TP53
    YWHAE          
      Other solid tumors ALK APC ARID1A ASPSCR1 ATF1 ATIC 152
    BAP1 BCOR BRCA1 BRCA2 CAMTA1 CARS
    CCNB2 CDK4 CDKN2A CIC CITED2 CLTC
    COL1A1 COL6A3 CREB1 CREB3L1 CREB3L2 CSF1
    CTNNB1 DDIT3 DDX3X DNAJB1 DUX4 EED
    EGFR ERBB2 ERG ETV1 ETV4 ETV6
    EWSR1 FEV FGFR2 FGFR3 FLI1 FOXL2
    FOXO1 FOXO4 FUS GLI1 HEY1 HGF
    HMGA2 IDH1 KRAS LEUTX MAML3 MDM2
    MYB MYOD1 NAB2 NCOA2 NF1 NFATC2
    NFIB NR4A3 NRAS NUTMI NUTM2A NUTM2B
    PALB2 PATZ1 PAX3 PAX7 PDGFB PDGFRA
    PRKACA PRKD1 RANBP2 ROS1 SDHA SDHB
    SDHC SDHD SMARCB1 SS18 SSX1 SSX2
    SSX4 STAT6 SUZ12 TAF15 TCF12 TERT
    TFE3 TFEB TFG TP53 TPM3 TPM4
    TRAF7 TSPAN31 VGLL2 WT1 WWTR1 YAP1
    YWHAE ZC3H7B        

    The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on the respective product pages.

    1. Includes key guideline biomarkers, emerging biomarkers, and pan-cancer biomarkers. Content analysis provided by Velsera based on software Knowledgebase v8.5 (February 2023).
    2. Genes with biomarkers of significance linked to current drug labels or guidelines.
    3. Genes with biomarkers of potential significance based on presence in clinical trials.
    4. CNS, central nervous system.

    Product comparison

      TruSight Oncology 500 TruSight Oncology 500 High-Throughput TruSight Oncology 500 ctDNA v2 
    Assay time 4–5 days from sample to results 4–5 days from sample to results 3-4 days from purified nucleic acid to variant report
    Automation capability Liquid handling robot(s) Liquid handling robot(s) Liquid handling robot(s)
    Automation details Explore available automation methods Explore available automation methods Explore available automation methods
    Cancer type Pan-cancer, Solid tumor Pan-cancer, Solid tumor Pan-cancer, Solid tumor
    Content specifications Targeted sequencing of DNA from 523 genes and RNA from 55 genes for a total of 1.94 Mb panel size. MSI and TMB measurement included. The optional TruSight Oncology 500 HRD kit (not available in Japan) content includes coverage of ~25K SNPs to assess homologous recombination deficiency through a comprehensive genomic instability score (LOH+TAI+LST) powered by Myriad Genetics. Targeted sequencing of DNA from 523 genes of interest and RNA from 55 genes, for a total of 1.94 Mb panel size. MSI and TMB measurement included. Targeted selection of 523 genes (full coding sequence) for a total of 1.94 Mb panel size.
    • Immuno-oncology biomarker coverage: TMB and MSI
    • Guideline coverage: Broad coverage of key guidelines for multiple solid tumor types
    • Clinical trial coverage: Over 600 clinical trials (based on Velsera Knowledgebase, as of February 2023).
    Description Assay that enables comprehensive genomic profiling from FFPE tissue and runs on the NextSeq 550 System or NextSeq 550Dx Instrument (in Research Mode) and can batch up to eight samples at a time. A high-throughput comprehensive NGS assay to identify key biomarkers in guidelines and >1K clinical trials from a streamlined workflow using the NextSeq 1000, NextSeq 2000, NovaSeq 6000, NovaSeq 6000Dx (in research mode) or the NovaSeq X Series. Includes coverage of immuno-oncology biomarkers TMB and MSI. Provides a noninvasive research method for comprehensive genomic profiling of liquid biopsy samples (ctDNA from blood plasma). This liquid biopsy approach provides insights about intra- and inter-tumor heterogeneity using a minimally invasive sample collection approach to complement tissue-based CGP.
    Hands-on time ~2.5 hr for automated workflow
    ~10.5 hr for manual workflow    		 ~2.5 hr for automated workflow
    ~10.5 hr for manual workflow    		 ~1.5 hr for automated workflow
    ~2.5 hr for manual workflow
    Input quantity 40 ng DNA and/or 40 ng RNA 40 ng DNA and/or 40–80 ng RNA 20 ng cfDNA (4 ml of plasma)
    Instruments NextSeq 550 System, NextSeq 550Dx in research mode NextSeq 2000 System, NextSeq 1000 System, NovaSeq X System, NovaSeq X Plus System, NovaSeq 6000Dx in research mode, NovaSeq 6000 System NovaSeq X System, NovaSeq X Plus System, NovaSeq 6000 System, NovaSeq 6000Dx in research mode
    Method Target enrichment, Targeted DNA sequencing, Targeted RNA sequencing Target enrichment, Targeted DNA sequencing, Targeted RNA sequencing Target enrichment, Targeted DNA sequencing
    Multiplexing Up to 8-plex

    NextSeq 1000 and 2000: P2 flow cell 8 samples, P3 flow cell 24 samples, P4 flow cell 36 samples.
    NovaSeq 6000/Dx: SP flow cell 16 samples, S1 flow cell 32 samples, S2 flow cell 72 samples, S4 flow cell 192 samples.

    NovaSeq X Series*: 1.5B cartridge 32 samples, 10B cartridge 192 samples, 25B 480 samples..

    		 NovaSeq X Series: 4 samples on 1.5B flow cell, 24 samples on 10B flow cell NovaSeq 6000 System: 8 samples on S2 flow cell, 24 samples on S4 flow cell, 192 indexes maximum
    Nucleic acid type RNA, DNA RNA, DNA DNA
    Sample throughput 8 samples/run NextSeq 1000 and 2000: 8-36 samples/run, NovaSeq 6000/Dx: 16-192 samples/run, NovaSeq X: 32-480 samples/run, NovaSeq X Plus: 32-960 samples/run 4-48 samples/run
    Specialized sample types FFPE Tissue FFPE Tissue Circulating tumor DNA, Blood
    Species category Human Human Human
    Technology Sequencing Sequencing Sequencing
    Variant class Gene fusions, Transcript variants, Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs), Loss of heterozygosity (LOH), Somatic variants, Novel transcripts, Single nucleotide polymorphisms (SNPs), Structural variants Gene fusions, Somatic variants, Novel transcripts, Structural variants, Transcript variants, Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs) Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs)

    FAQ

    Showing 1 - 3 / 3 Results

    Resources

    Thumbnail

    TruSight Oncology 500 HRD at Oncopole Toulouse

    Homologous recombination deficiency (HRD) is an important biomarker in ovarian cancer. Hear about TSO 500 HRD assay performance from Dr. Guillaume Bataillon at the Oncopole Toulouse laboratory in France.

    Speak to a specialist

    Contact an Illumina representative to learn more about TruSight Oncology 500 products and find the right assay for your needs.

    *HRD is available through an accessory kit to assess the Genomic Instability Score (GIS). HRD is only available with the addition of the TruSight Oncology 500 HRD kit to TruSight Oncology 500. Not available in Japan. 
    †8 samples/run for TruSight Oncology 500 and 8–16 samples/run for TruSight Oncology 500 HRD; 16–192 samples/run for TruSight Oncology 500 High-Throughput.

     

    References

    1. Content analysis provided by Pierian Knowledgebase v8.5, February 2023.
    2. O'Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547-560. doi:10.1016/j.molcel.2015.10.040 
    3. Yamamoto H, Hirasawa A. Homologous recombination deficiencies and hereditary tumors. Int J Mol Sci. 2021;23(1):348. doi:10.3390/ijms23010348